

Amendment Statement of Principles

concerning

SARCOIDOSIS  
(Balance of Probabilities)

(No. 14 of 2019)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(3) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 21 December 2018

|  |
| --- |
| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of: |
| Professor Nicholas Saunders AO  Chairperson |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Amendment 3

1. Name

This is the Amendment Statement of Principles concerning *sarcoidosis* *(Balance of Probabilities)* (No. 14 of 2019).

1. Commencement

This instrument commences on 28 January 2019.

1. Authority

This instrument is made under subsections 196B(3) and (8) of the *Veterans' Entitlements Act 1986*.

1. Amendment

The Statement of Principles concerning *sarcoidosis (Balance of Probabilities)* (No. 60 of 2016) (Federal Register of Legislation No. F2016L01143) is amended in the following manner:

|  |  |
| --- | --- |
| **Section** | **Amendment** |
| 9(1) | *Replace the existing factor in subsection 9(1) with the following*:  being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical onset of sarcoidosis;  Note: ***specified list of drugs*** is defined in the Schedule 1 - Dictionary. |
| 9(3) | *Replace the existing factor in subsection 9(3) with the following*:  being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical worsening of sarcoidosis;  Note: ***specified list of drugs*** is defined in the Schedule 1 - Dictionary. |
| Schedule 1 – Dictionary | *Insert the following definition of "specified list of drugs" in alphabetical order:*  ***specified list of drugs*** means:   1. BRAF/MEK inhibitors, including, but not limited to, vemurafenib, dabrafenib and trametinib; 2. immune checkpoint inhibitors, including, but not limited to, ipilimumab, pembrolizumab and nivolumab; or 3. interferons. |